Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Drug Interaction Study of Colchicine and Theophylline
- First Posted Date
- 2012-05-17
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- Takeda
- Target Recruit Count
- 30
- Registration Number
- NCT01601132
- Locations
- 🇺🇸
Worlwide Clinical Trials Drug Development Solutions, Clinical Research Services, San Antonio, Texas, United States
Double Blind Comparative Study of TAK-875
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2013-04-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 80
- Registration Number
- NCT01585792
Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
Phase 3
Completed
- Conditions
- Post-Stroke Cognitive Impairment (PSCI)
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-04-23
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 503
- Registration Number
- NCT01582854
- Locations
- 🇷🇺
Nycomed Investigational Site, Tomsk, Russian Federation
A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 30
- Registration Number
- NCT01568385
A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 27
- Registration Number
- NCT01568398
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 3
Completed
- Conditions
- Refractory Multiple MyelomaRelapsed Multiple Myeloma
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 722
- Registration Number
- NCT01564537
- Locations
- 🇺🇸
University of Arkansas Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Pacific Cancer Medical Center Inc, Anaheim, California, United States
🇺🇸West Contra Costa Healthcare District, Berkeley, California, United States
Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder
Phase 2
Completed
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2015-02-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 602
- Registration Number
- NCT01564862
Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
Phase 3
Terminated
- Conditions
- Glycemic Control
- Interventions
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2016-06-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 916
- Registration Number
- NCT01549964
Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1
- Registration Number
- NCT01549977
A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer
Phase 3
Completed
- Conditions
- Premenopausal Breast Cancer
- Interventions
- Drug: TAP-144-SR(6M)Drug: TAP-144-SR(3M)
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2015-11-26
- Lead Sponsor
- Takeda
- Target Recruit Count
- 167
- Registration Number
- NCT01546649
© Copyright 2025. All Rights Reserved by MedPath